Nipro

Nipro CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Nipro (8086.T) as of Oct 28, 2026 is 114.04 %. In the previous year, CapEx to Operating Cash Flow Ratio was 111.90 % — a change of 1.91% (higher).

CapEx/OCF

114.04 %

YoY

1.91%

Last updated:

CapEx to Operating Cash Flow Ratio of Nipro is 2026 114.04 % . CapEx to Operating Cash Flow Ratio of Nipro was 2025 111.90 % . It decreases by 1.91% higher compared to the previous year.

The Nipro CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2019
135.36 JPY
Jan 1, 2020
155.57 JPY
Jan 1, 2021
77.44 JPY
Jan 1, 2022
116.99 JPY
Jan 1, 2023
816.11 JPY
Jan 1, 2024
129.24 JPY
Jan 1, 2025
111.90 JPY
Jan 1, 2026
114.04 JPY
The Nipro CapEx/OCF history
YEARCapEx/OCFYoY
114.04 %+1.91%
111.90 %-13.42%
129.24 %-84.16%
816.11 %+597.60%
116.99 %+51.07%
77.44 %-50.22%
155.57 %+14.93%
135.36 %-11.33%
152.65 %-20.44%
191.87 %+36.96%
140.09 %-3.64%
145.38 %+7.16%
135.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nipro Stock analysis

What does Nipro do? Nipro Corp is a Japanese company that was originally founded under the name Niki Shoji. The company was established in 1954 and initially produced steel pipes and accessories. In 1964, the company changed its name to Nipro Corp and expanded its business to the production of medical devices and instruments. Since then, Nipro Corp has become a major player in the global market for medical products and services. The business model of Nipro Corp is based on the design, manufacturing, and sale of a wide range of medical products, including dialysis machines, artificial organs, blood glucose meters, and infusion devices. The company is also active in the pharmaceutical and healthcare industries, offering various related services such as clinical trials. Nipro Corp is divided into various divisions, including Nipro Medical Corporation, which produces and sells the company's medical product range. This division is divided into three departments: dialysis technology, transfusion and infusion department, and the artificial organs department, which includes various products such as heart-lung machines and artificial kidneys. Another important division is Nipro Pharma Corporation, which focuses on the development, manufacturing, and sale of pharmaceuticals. The company has a strong presence in this division in the Asian market and is currently expanding into Europe and the United States. Another important area in which Nipro Corp is active is the manufacturing of glass and plastic products, particularly glass ampoules for storing medications and plastic products for medical use. In addition to its main business areas, Nipro Corp also offers a wide range of products and services for environmental technology, the semiconductor industry, and the electronics industry. The company is also involved in the production of solar energy products and has filed various patents in this field. Innovation and quality control are two important focuses of Nipro Corp. The company is heavily dedicated to researching and developing new products and technologies, as well as building strong business relationships with its customers. One of the key strategies of the company is to align its research and development activities with the needs of its customers and end-users to ensure that its products meet their requirements and expectations. Another focus of Nipro Corp is quality assurance and control. The company has a strict quality management system that is applied in all stages of the manufacturing process to ensure that its products meet the highest international standards. Overall, Nipro Corp has become a major player in the global market for medical products and services. With its wide range of products and services, focus on innovation and quality, and strong presence in the Asian market, the company is in a strong position to continue growing and evolving. Nipro is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nipro stock

CapEx to Operating Cash Flow Ratio of Nipro is 114.04 % in 2026.

CapEx to Operating Cash Flow Ratio of Nipro changed from 111.90 % to 114.04 %, representing a 1.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Nipro since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Nipro with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nipro

All Key Metrics — Nipro